BRPI0417916A - proteìna de fusão de fc-eritropoietina com farmacocinética melhorada - Google Patents

proteìna de fusão de fc-eritropoietina com farmacocinética melhorada

Info

Publication number
BRPI0417916A
BRPI0417916A BRPI0417916-1A BRPI0417916A BRPI0417916A BR PI0417916 A BRPI0417916 A BR PI0417916A BR PI0417916 A BRPI0417916 A BR PI0417916A BR PI0417916 A BRPI0417916 A BR PI0417916A
Authority
BR
Brazil
Prior art keywords
epo
improved pharmacokinetics
fusion protein
fusion proteins
increased
Prior art date
Application number
BRPI0417916-1A
Other languages
English (en)
Inventor
Stephen D Gillies
Scott Lauder
Dorothee Kress
Robert Mueller
Hanns-Christian Mahler
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0417916A publication Critical patent/BRPI0417916A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"PROTEìNA DE FUSãO DE Fc-ERITROPOIETINA COM FARMACOCINéTICA MELHORADA". A presente invenção refere-se a novas proteínas de fusão de FcEPO altamente sialiladas preferivelmente compreendendo algumas modificações na porção de Fc como também na porção de EPO e tendo farmacocinética melhorada. Especificamente, as proteínas de Fc-EPO têm uma meia-vida em soro prolongada e potência in vivo aumentada. As proteínas de fusão de Fc-EPO sintetizadas em células de BHK têm meias-vidas dramaticamente prolongadas em soro e potência in vivo aumentada quando comparadas às proteínas de fusão de Fc-EPO correspondentes produzidas em outras linhagens celulares, como, por exemplo, células de NS/0.
BRPI0417916-1A 2003-12-31 2004-12-22 proteìna de fusão de fc-eritropoietina com farmacocinética melhorada BRPI0417916A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53385803P 2003-12-31 2003-12-31
PCT/EP2004/014608 WO2005063808A1 (en) 2003-12-31 2004-12-22 Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS

Publications (1)

Publication Number Publication Date
BRPI0417916A true BRPI0417916A (pt) 2007-04-10

Family

ID=34738878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417916-1A BRPI0417916A (pt) 2003-12-31 2004-12-22 proteìna de fusão de fc-eritropoietina com farmacocinética melhorada

Country Status (13)

Country Link
US (2) US7465447B2 (pt)
EP (1) EP1699821B1 (pt)
JP (2) JP2008504008A (pt)
KR (1) KR20060124656A (pt)
CN (1) CN1902222A (pt)
AU (1) AU2004309063B2 (pt)
BR (1) BRPI0417916A (pt)
CA (1) CA2551916C (pt)
DK (1) DK1699821T3 (pt)
ES (1) ES2387028T3 (pt)
PT (1) PT1699821E (pt)
RU (1) RU2370276C2 (pt)
WO (1) WO2005063808A1 (pt)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
PL206701B1 (pl) 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004309050B2 (en) * 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
BRPI0417916A (pt) * 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1819728B1 (en) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7 variants with reduced immunogenicity
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PL1969007T4 (pl) 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP1966238B1 (en) 2005-12-30 2012-04-25 Merck Patent GmbH Interleukin-12p40 variants with improved stability
PT1966245E (pt) * 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
NZ572379A (en) * 2006-04-05 2012-06-29 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2027151A2 (en) * 2006-05-15 2009-02-25 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
SI1873166T1 (sl) * 2006-06-30 2011-01-31 Conaris Res Inst Ag IZBOLJĹ ANI sgp 130Fc DIMERJI
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
JP2010517529A (ja) 2007-02-02 2010-05-27 アムジエン・インコーポレーテツド ヘプシジン及びヘプシジン抗体
US8283319B2 (en) 2007-02-12 2012-10-09 Csl Behring Gmbh Therapeutic application of Kazal-type serine protease inhibitors
PL1961821T3 (pl) 2007-02-22 2010-01-29 Polymun Scient Immunbiologische Forschung Gmbh Erytropoetynowe białko fuzyjne
US20110077383A1 (en) * 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
BRPI0814465B1 (pt) * 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
AU2009206306B2 (en) 2008-01-25 2013-06-06 Amgen Inc. Ferroportin antibodies and methods of use
US7846744B2 (en) 2008-04-22 2010-12-07 Ravetch Jeffrey V Methods of identifying anti-inflammatory compounds
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
EP2184070A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
AU2009313902B9 (en) 2008-11-13 2014-03-27 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of BMP-6
KR20120030383A (ko) 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질
CN102712688B (zh) * 2009-09-23 2015-06-24 通益制药有限公司 重组人红细胞生成素(epo)的纯化方法、由此纯化的epo以及包含纯化的epo的药物组合物
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
IL297588A (en) 2009-11-02 2022-12-01 Univ Washington Therapeutic nuclease preparations and methods
JP5959440B2 (ja) 2010-01-19 2016-08-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 病原体の検出および治療のための改変オプソニン
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP2575935B2 (en) 2010-06-07 2023-08-23 Amgen Inc. Drug delivery device
US20130331554A1 (en) * 2010-11-15 2013-12-12 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
US9982227B2 (en) 2011-03-08 2018-05-29 University Of Maryland, Baltimore County System and method for production of on-demand proteins in a portable unit for point of care delivery
US10774304B2 (en) 2011-03-08 2020-09-15 University Of Maryland, Baltimore County System and method for production of on-demand proteins in a portable unit for point of care delivery
PL2683397T3 (pl) 2011-03-09 2018-01-31 Csl Behring Gmbh Inhibitory czynnika XII do podawania w zabiegach medycznych obejmujących kontakt z powierzchniami sztucznymi
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
EP2704737B1 (en) 2011-04-29 2018-01-10 University of Washington Therapeutic nuclease compositions and methods
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
KR102042982B1 (ko) 2011-07-22 2019-11-11 체에스엘 베링 게엠베하 억제성 항-ｘｉｉ/ｘｉｉａ 인자 모노클로날 항체 및 이들의 사용
IL301153B2 (en) 2011-10-14 2024-05-01 Amgen Inc Syringe and assembly method
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
DK2822575T3 (da) * 2012-03-03 2020-06-15 Immungene Inc Manipulerede, muterede antistof-interferon-fusionsmolekyler
CN102690354B (zh) * 2012-05-14 2015-03-25 安源生物科技(上海)有限公司 重组二聚化抗凝血酶III-Fc融合蛋白及其哺乳动物细胞高效表达系统
EP4234694A3 (en) 2012-11-21 2023-09-06 Amgen Inc. Drug delivery device
EP2964255B1 (en) 2013-03-08 2020-11-04 CSL Behring GmbH Treatment and prevention of remote ischemia-reperfusion injury
DK2968503T3 (en) 2013-03-15 2018-12-03 Intrinsic Lifesciences Llc ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
TWI580452B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
CN105377327B (zh) 2013-03-22 2021-06-22 安姆根有限公司 注射器及装配方法
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
CN105339010A (zh) 2013-06-28 2016-02-17 德国杰特贝林生物制品有限公司 使用因子xii抑制剂和c1-抑制剂的联合疗法
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
EP3060281B1 (en) 2013-10-24 2019-01-30 Amgen Inc. Drug delivery system with temperature-sensitive control
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
BR112016019893B1 (pt) * 2014-03-05 2023-02-14 Ultragenyx Pharmaceutical Inc Composição
US10722655B2 (en) 2014-05-07 2020-07-28 Amgen Inc. Autoinjector with shock reducing elements
CN106470716B (zh) 2014-06-03 2020-07-17 安姆根有限公司 可控制药物递送系统和使用方法
CN106456778A (zh) 2014-06-18 2017-02-22 德国杰特贝林生物制品有限公司 在神经创伤性病患中使用因子xii抑制剂进行治疗
ES2844232T3 (es) 2014-07-02 2021-07-21 CSL Behring Lengnau AG Factor de Von Willebrand modificado
FR3024453B1 (fr) * 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
ES2898469T3 (es) 2014-12-19 2022-03-07 Amgen Inc Dispositivo de administración de medicamentos con sensor de proximidad
RU2673548C1 (ru) * 2015-01-09 2018-11-28 Генексин, Инк. Способ лечения анемии с применением композиции ЕРО длительного действия
JP6484345B2 (ja) 2015-02-17 2019-03-20 アムジエン・インコーポレーテツド 固定及び／または戻りが真空によって支援された薬物送達装置
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
CN107787328B (zh) 2015-05-22 2021-08-06 康诺贝林伦瑙有限公司 用于治疗血友病的截短的血管性血友病因子多肽
WO2016188905A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
US11820807B2 (en) * 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
EP3331549B1 (en) 2015-08-06 2020-12-23 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
KR101847169B1 (ko) * 2015-10-07 2018-04-09 주식회사 녹십자 지속형 에리트로포이에틴 함유 조성물
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP3400238B1 (en) 2016-01-07 2021-05-19 CSL Behring Lengnau AG Mutated von willebrand factor
SG10201912498YA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated truncated von willebrand factor
EP4035711A1 (en) 2016-03-15 2022-08-03 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
CN109071629A (zh) 2016-04-06 2018-12-21 杰特有限公司 治疗动脉粥样硬化的方法
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
US10988284B2 (en) 2016-05-13 2021-04-27 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
CN105884906B (zh) * 2016-05-27 2021-11-19 广州太力生物医药科技有限公司 一种长效人促红细胞生成素融合蛋白的纯化方法
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
EP3592402A1 (en) 2017-03-07 2020-01-15 Amgen Inc. Needle insertion by overpressure
MX2019010671A (es) 2017-03-09 2019-10-21 Amgen Inc Mecanismo de insercion para dispositivo de administracion de farmacos.
CN110446499A (zh) 2017-03-20 2019-11-12 豪夫迈·罗氏有限公司 一种体外糖基工程化红细胞生成刺激蛋白的方法
BR112019020053B1 (pt) 2017-03-28 2023-10-10 Amgen Inc Máquina para acoplar uma haste de êmbolo a um conjunto de seringa e método de utilização da referida máquina
US11904143B2 (en) 2017-06-08 2024-02-20 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3063920A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
US11141466B2 (en) 2017-06-22 2021-10-12 CSL Behring Lengnau AG Modulation of FVIII immunogenicity by truncated VWF
US11395880B2 (en) 2017-06-23 2022-07-26 Amgen Inc. Electronic drug delivery device
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (fr) 2017-10-04 2020-08-12 Amgen Inc Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
CN116832271A (zh) 2017-11-10 2023-10-03 安进公司 用于药物递送装置的柱塞
CN111263651B (zh) 2017-11-16 2022-06-17 安进公司 具有停顿和终点检测的自动注射器
MX2020004996A (es) 2017-11-16 2020-08-27 Amgen Inc Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
CN107937425A (zh) * 2017-12-27 2018-04-20 北京四环生物制药有限公司 长效重组人促红素的生产方法
WO2019209078A1 (ko) * 2018-04-26 2019-10-31 주식회사 굳티셀 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
MA53379A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
US20210228797A1 (en) 2018-07-31 2021-07-29 Amgen Inc. Fluid path assembly for a drug delivery device
AU2019347710A1 (en) 2018-09-24 2021-02-04 Amgen Inc. Interventional dosing systems and methods
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
MA53815A (fr) 2018-10-02 2022-01-05 Amgen Inc Systèmes d'injection pour administration de médicament avec transmission de force interne
US20210338936A1 (en) 2018-10-05 2021-11-04 Amgen Inc. Drug delivery device having dose indicator
US20200114082A1 (en) 2018-10-15 2020-04-16 Amgen Inc. Drug delivery device having damping mechanism
TW202031306A (zh) 2018-10-15 2020-09-01 美商安進公司 用於藥物遞送裝置之平台組裝方法
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020091981A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2020263289A1 (en) 2019-04-24 2021-09-16 Amgen Inc. Syringe sterilization verification assemblies and methods
AU2020277640A1 (en) 2019-05-17 2022-01-20 Csl Behring Ag Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
CU24704B1 (es) * 2019-09-05 2024-04-08 Ct Inmunologia Molecular Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
CN111499764B (zh) * 2020-04-02 2022-02-08 北京翼方生物科技有限责任公司 一种具有促红细胞生成素活性的长效融合蛋白
US20230357341A1 (en) * 2020-06-10 2023-11-09 Bica Therapeutics Inc. Fusion protein containing erythropoietin polypeptide
EP4247416A1 (en) 2020-11-20 2023-09-27 CSL Behring GmbH Method for treating antibody-mediated rejection
CA3206884A1 (en) 2021-02-01 2022-08-04 Kevin AKERET Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
CN117321074A (zh) 2021-05-07 2023-12-29 瑞士杰特贝林生物制品有限公司 用于产生重组触珠蛋白(Hp)β链的表达系统
EP4341161A1 (en) 2021-05-21 2024-03-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023211805A1 (en) * 2022-04-26 2023-11-02 The Regents Of The University Of California Hhip-fc fusion proteins and uses thereof
WO2023222040A1 (zh) * 2022-05-17 2023-11-23 广州汉腾生物科技有限公司 重组促红细胞生成素及其应用
WO2024047219A1 (en) 2022-09-02 2024-03-07 Csl Behring Ag Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US5082658A (en) 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
EP0275636B1 (en) * 1987-01-19 1993-07-21 Canon Kabushiki Kaisha Color toner and two-component developer containing same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6750329B1 (en) 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE123065T1 (de) 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd Proteine und deren herstellung.
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen
US20020037558A1 (en) 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US5335176A (en) * 1991-12-02 1994-08-02 Koyo Seiko Co., Ltd. Safety system for vehicles
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
DE4228839A1 (de) 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
WO1994025055A1 (en) 1993-04-29 1994-11-10 Abbott Laboratories Erythropoietin analog compositions and methods
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5514087A (en) * 1994-08-26 1996-05-07 Karl Storz Gmbh & Co. Self-regulating insufflator
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ATE271606T1 (de) 1995-03-10 2004-08-15 Genentech Inc Die aktivierung von rezeptoren durch gas6
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5856293A (en) * 1996-08-08 1999-01-05 Colgate Palmolive Company Light duty liquid cleaning compositions
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
MXPA00010070A (es) * 1998-04-15 2004-03-10 Lexigen Pharm Corp Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
CA2328081A1 (en) * 1998-04-17 1999-10-28 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
US5946778A (en) * 1998-08-11 1999-09-07 Mcgarity; Ronald M. Clip with retractable operating levers
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
DK1107989T3 (da) * 1998-08-25 2010-05-25 Merck Patent Gmbh Ekspression og eksport af angiostatin og endostatin som immunfusiner
US6419644B1 (en) * 1998-09-08 2002-07-16 Scimed Life Systems, Inc. System and method for intraluminal imaging
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
CN1341121A (zh) * 1999-01-07 2002-03-20 利思进药品公司 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运
JP2003528573A (ja) 1999-05-06 2003-09-30 ウエイク・フオレスト・ユニバーシテイ 免疫応答を導き出す抗原を同定するための組成物および方法
MXPA01011845A (es) 1999-05-19 2002-06-21 Lexigen Pharm Corp Expresion y exportacion de proteinas de interferon-alfa como proteinas de fusion fc.
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1200561B1 (de) * 1999-08-05 2006-06-14 Baxter Aktiengesellschaft Rekombinanter stabiler zellklon, seine herstellung und verwendung
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
CA2391080A1 (en) * 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
PT1257297E (pt) * 2000-02-24 2006-12-29 Philogen Spa Composições e método para tratamento da angiogénese em lesões patológicas
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
PT1274728E (pt) * 2000-04-21 2008-06-20 Amgen Inc Métodos e composições para a prevenção e tratamento de anemia
EP1285072A2 (en) 2000-05-12 2003-02-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
BR0116803A (pt) * 2001-01-18 2004-02-17 Merck Patent Gmbh Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
ES2309167T3 (es) * 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
PL206701B1 (pl) 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2003106484A1 (en) * 2002-06-17 2003-12-24 Chr. Hansen A/S Improved method of producing an aspartic protease in a recombinant host organism
MXPA05006384A (es) 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004309050B2 (en) 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
BRPI0417916A (pt) * 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
EP1819728B1 (en) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7 variants with reduced immunogenicity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
PT1966245E (pt) * 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
EP1966238B1 (en) * 2005-12-30 2012-04-25 Merck Patent GmbH Interleukin-12p40 variants with improved stability
CN101346395A (zh) * 2005-12-30 2009-01-14 默克专利有限公司 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
CA2656700A1 (en) * 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses

Also Published As

Publication number Publication date
KR20060124656A (ko) 2006-12-05
US7465447B2 (en) 2008-12-16
CA2551916A1 (en) 2005-07-14
RU2006127554A (ru) 2008-02-10
WO2005063808A1 (en) 2005-07-14
CN1902222A (zh) 2007-01-24
JP2012107042A (ja) 2012-06-07
US20090092607A1 (en) 2009-04-09
AU2004309063B2 (en) 2010-10-28
PT1699821E (pt) 2012-08-23
AU2004309063A1 (en) 2005-07-14
ES2387028T3 (es) 2012-09-12
US20050192211A1 (en) 2005-09-01
RU2370276C2 (ru) 2009-10-20
JP2008504008A (ja) 2008-02-14
DK1699821T3 (da) 2012-07-16
EP1699821A1 (en) 2006-09-13
CA2551916C (en) 2014-04-29
EP1699821B1 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
BRPI0417916A (pt) proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
NO2017027I1 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
MXPA01010360A (es) Produccion de proteinas recombinantes en una celula humana.
BR0314092A (pt) proteìnas de fusão de transferrina modificadas
MXPA04005266A (es) Inmunocitocinas con selectividad modulada.
BR9812547A (pt) Proteìnas de fusão compreendendo proteìnas hiv-1 tat e/ou nef
BR0314093A (pt) Proteìnas de fusão de transferrina modificada-anticorpo
BRPI0606934A2 (pt) Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
EP1389209A4 (en) FOLAT MIMETICS AND THEIR FOLAT RECEPTOR BINDING CONJUGATES
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
BR0114475A (pt) Célula para a produção de composição de anticorpo
HUP0400466A2 (hu) G-CSF konjugátumok
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
SG169351A1 (en) Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
CY1105772T1 (el) Συνθεσεις και μεθοδοι για βελτιωμενη κυτταρικη καλλιεργεια
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
BR0313212A (pt) Aditivos de ácido de polialquileno glicol
SG65593A1 (en) Totally synthetic affinity reagents
DE69505804D1 (de) Afamin: ein menschliches serum albumin ähnliches protein
GB0018901D0 (en) Peptides presented by cells
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
KR930008148A (ko) 변이 인간 프로우로키나아제
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
Andersson Production of Clotting Factors Through Biotechnology

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.